The European Medicines Agency (EMA) will issue a new opinion “late on Wednesday” on the relationship between the AstraZeneca against Covid-19 and the thrombi in some vaccinated.
“In close contact with the EMA on the evaluation of pharmacovigilance of the AstraZeneca vaccine. The evaluation is expected late on Wednesday,” the European Commissioner for Health and Food Safety, Stella Kyriakides, has advanced in a publication on social networks.
The head of the EMA’s vaccination strategy, Marco Cavaleri, confirmed this Tuesday an “association” between the AstraZeneca vaccine and the thrombotic events that some vaccinates are experiencing, mainly women under 50 with platelet deficiency. “We can say, there is clearly an association with the vaccine. However, there is still we don’t know what causes this reaction. These platelet-deficient cerebral thromboses appear to be the main event to investigate. In summary: in the next few hours we will say that there is a connection, but we still have to understand how it happens “, he has detailed in an interview with the Italian newspaper ‘Il Messagero’.
The head of the EMA has recognized that “there are more cases of cerebral thrombosis with platelet deficiency among young people than would be expected”, mainly in women under 50 years of age. “Although there have also been cases between 50 and 60 years and there are also men, around 20 percent. The average age is around 45-47 years,” he pointed out.
In any case, Cavalieri has not openly ruled on whether an age group or group will be set that cannot be administered this Wednesday, at the meeting organized by the EMA to issue a new opinion on the safety of the vaccine. “I understand the European need to have a unique and strong voice, but I don’t know if we will have that kind of indication as soon as this week. But the product information will certainly be updated, stating that adverse events are related to the vaccine. It will be clearly established, “he said.
Last Wednesday, the executive director of the EMA, Emer Cooke, pointed out that, although “a causal relationship with the vaccine has not been demonstrated,” it is “possible”, so “new analyzes are being carried out.” To that date, according to Cooke, a total of 44 cases of cerebral venous thrombosis have been detected in 9.2 million people vaccinated with the injection of AstraZeneca in Europe, although it does not include all the 31 cases reported yesterday in Germany. Total, there have been 14 deaths in Europe that are under investigation for the AstraZeneca vaccine, although not all for these types of blood clots. “If we look at the exposure adjusted for age, we calculate a risk of one per 100,000 in those under 60 years old,” he explained.
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.